Related Experiment Video
Updated: May 30, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines
Xiaoming Li1, Mark Hilgers, Mark Cunningham
1Trius Therapeutics, San Diego, CA 92121, United States.
Abstract:
Dihydrofolate reductase (DHFR) inhibitors such as trimethoprim (TMP) have long played a significant role in the treatment of bacterial infections. Not surprisingly, after decades of use there is now bacterial resistance to TMP and therefore a need to develop novel antibacterial agents with expanded spectrum including these resistant strains. In this study, we investigated the optimization of 2,4-diamnoquinazolines for antibacterial potency and selectivity. Using structure-based drug design, several 7-aryl-2,4-diaminoquinazolines were discovered that have excellent sub-100 picomolar potency against bacterial DHFR. These compounds have good antibacterial activity especially on gram-positive pathogens including TMP-resistant strains.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Diazonium Group Substitution: –OH and –H
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Diazonium Group Substitution with Halogens and Cyanide: Sandmeyer and Schiemann Reactions
Gene Regulation in Microbial Communities: Quorum Sensing
